Next Article in Journal
Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma
Next Article in Special Issue
c-Src and EGFR Inhibition in Molecular Cancer Therapy: What Else Can We Improve?
Previous Article in Journal
Comparative Analysis of Age- and Gender-Associated Microbiome in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma
Previous Article in Special Issue
The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC)
Open AccessFeature PaperReview

Src Family Kinases as Therapeutic Targets in Advanced Solid Tumors: What We Have Learned So Far

1
Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila,67100 L’Aquila, Italy
2
Biomedicine and Advanced Technologies Rieti Center “Sabina Universitas”, 02100 Rieti, Italy
3
Department of Biological and Ecological Science, University of Tuscia, 01100 Viterbo, Italy
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(6), 1448; https://doi.org/10.3390/cancers12061448
Received: 13 May 2020 / Revised: 29 May 2020 / Accepted: 31 May 2020 / Published: 2 June 2020
(This article belongs to the Special Issue The Role of Src Kinase Family in Cancer)
Src is the prototypal member of Src Family tyrosine Kinases (SFKs), a large non-receptor kinase class that controls multiple signaling pathways in animal cells. SFKs activation is necessary for the mitogenic signal from many growth factors, but also for the acquisition of migratory and invasive phenotype. Indeed, oncogenic activation of SFKs has been demonstrated to play an important role in solid cancers; promoting tumor growth and formation of distant metastases. Several drugs targeting SFKs have been developed and tested in preclinical models and many of them have successfully reached clinical use in hematologic cancers. Although in solid tumors SFKs inhibitors have consistently confirmed their ability in blocking cancer cell progression in several experimental models; their utilization in clinical trials has unveiled unexpected complications against an effective utilization in patients. In this review, we summarize basic molecular mechanisms involving SFKs in cancer spreading and metastasization; and discuss preclinical and clinical data highlighting the main challenges for their future application as therapeutic targets in solid cancer progression View Full-Text
Keywords: Src; src family tyrosine kinases; cancer metastasization; cancer migration; cancer invasion; epithelial-to-mesenchymal transition; clinical trial; targeted therapy; dasatinib Src; src family tyrosine kinases; cancer metastasization; cancer migration; cancer invasion; epithelial-to-mesenchymal transition; clinical trial; targeted therapy; dasatinib
Show Figures

Graphical abstract

MDPI and ACS Style

Martellucci, S.; Clementi, L.; Sabetta, S.; Mattei, V.; Botta, L.; Angelucci, A. Src Family Kinases as Therapeutic Targets in Advanced Solid Tumors: What We Have Learned So Far. Cancers 2020, 12, 1448.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop